- Title
- A phase III, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of therapy among patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-OV81/NCRI/RAMP 301
- Creators
- Rachel Grisham - Memorial Sloan Kettering Cancer CenterBradley Monk - University of ArizonaEls Nieuwenhuysen - University Hospitals Leuven, BelgiumKathleen Moore - University of Oklahoma Health Sciences CenterMichel Fabbro - Institut du Cancer de Montpellier, Montpellier, FranceDavid O'Malley - The Ohio State UniversityAna Oaknin - Vall d'Hebron Hospital UniversitariPremal Thaker - Washington University School in St. Louis, St. Louis, MO, United StatesAmit Oza - Princess Margaret Cancer Centre, University Health Network, Toronto, CanadaNicoletta Colombo - University of MilanStephanie Lustgarten - VerastemLouis Denis - VerastemSusana Banerjee - The Royal Marsden and Institute of Cancer Research, London, United Kingdom
- Publication Details
- Gynecologic oncology, Vol.190, pp.S282-S283
- Publisher
- Elsevier Inc
- Identifiers
- 991006118536802656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
A phase III, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of therapy among patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-OV81/NCRI/RAMP 301
Gynecologic oncology, Vol.190, pp.S282-S283
11/2024
Metrics
3 Record Views